Trial Profile

Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis: a Phase 2 Non-comparative Randomised Controlled Trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dolutegravir (Primary) ; Dolutegravir/lamivudine/tenofovir (Primary)
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms RADIANT-TB

Most Recent Events

22 Feb 2023 Results presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023
21 Jul 2022 Status changed from active, no longer recruiting to completed.
24 Apr 2022 Planned End Date changed from 31 Aug 2022 to 30 Jun 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com